Track Lisata Therapeutics Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Lisata Therapeutics Inc. Common Stock LSTA · Stock Open Lisata Therapeutics Inc. Common Stock in new tab

1.04 USD
Add to portfolio
EPS
-1.60
P/B
1.18
ROE
-91.41
Beta
0.80
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateAug. 6, 2026
EPS-1.60
Book Value1.20
Price to Book1.18
% Insiders20.887%
Growth
Revenue Growth-0.90%
Estimates
Forward P/E-1.22
Forward EPS-1.16

DCF Valuation

Tweak assumptions to recompute fair value for Lisata Therapeutics Inc. Common Stock (LSTA)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Lisata Therapeutics Inc. Common Stock Logo Lisata Therapeutics Inc. Common Stock Analysis (LSTA)

United States Health Care Official Website Stock

Is Lisata Therapeutics Inc. Common Stock a good investment? Lisata Therapeutics Inc. Common Stock (LSTA) is currently trading at 1.04 USD.

Earnings Schedule: Lisata Therapeutics Inc. Common Stock is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is -1.16.

Investor FAQ

Does Lisata Therapeutics Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Lisata Therapeutics Inc. Common Stock?

Lisata Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -1.60.

Company Profile

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. Lisata Therapeutics, Inc. was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. in September 2022. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. As of July 21, 2026, Lisata Therapeutics, Inc. operates as a subsidiary of Kuva Labs, Inc.

Exchange Ticker
NMS (United States) LSTA
Trades
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
▸2013
0.00 USD
Oct. 28, 2013 0.0021
▸2011
0.00 USD
April 4, 2011 0.0002
Stock Splits
Split Date Split Ratio to 1
Aug. 31, 2006 0.100000
Aug. 9, 2007 0.100000
July 16, 2013 0.100000
July 28, 2016 0.100000
Sept. 15, 2022 0.066667
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion